Navigation Links
Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annual Meeting
Date:12/8/2008

y, Philadelphia, PA; SCHWARZ BIOSCIENCES, Inc., (a member of the UCB Group), Research Triangle Park, NC, United States

Evaluation of Lacosamide Efficacy in Subjects with Partial-Onset Seizures Across the Dose Range Used in Phase II/III Clinical Trials

In the individual trials and pooled analysis in this evaluation, Vimpat(R) significantly reduced seizures at all doses studied (200, 400, and 600 mg/day). The individual trials demonstrated that:

-- The 400 and 600 mg/day Vimpat(R) dose groups were significantly different from placebo for both primary efficacy endpoints in all trials using these doses.

-- The 200 mg/day Vimpat(R) dose group demonstrated significant seizure reduction versus placebo in the phase III trial (SP 755), but not in the phase II trial (SP667). To further evaluate the effectiveness of the 200 mg/day dose, a meta-analysis was conducted; results showed a significant difference compared to placebo for both primary endpoints.

The pooled results among patients entering the maintenance period demonstrated statistically significant reductions in seizure frequency at all doses studied compared to placebo:

-- Seizure frequency was significantly reduced by 33.5 percent for the 200 mg/day group (p <.05 ) and by more than 40 percent for the 400 and 600 mg/day groups (41.4 percent and 48.8 percent, respectively), compared with 19.2 percent for placebo (p<.0001).

-- Responder rates (patients with 50 percent or greater reduction in seizure frequency) were 34.8 percent for 200 mg/day (p <.05), 44.3 percent for 400 mg/day, and 48.6 percent for 600 mg/day, and 23.1 percent for placebo (p<.0001).

-- Additionally, there was a dose-responsive trend for improved seizure freedom rates among subjects who completed the maintenance period (2.7 percent, 3.3 percent, and 4.8 percent with increasing Vimpat(R) doses vs. 0.
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Genomic Health to Present Multiple New Studies at 31st Annual San Antonio Breast Cancer Symposium
2. Derma Sciences Announces Multiple Clinical Posters Featuring MEDIHONEY(R) and ALGICELL Ag(R) to be Presented at Upcoming Wound Care Conference
3. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
4. Senescos Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
5. Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug
6. Environmental Tectonics Corporation Announces a Multiple Sale of Hyperbaric Monoplace Chambers to Comprehensive Healthcare Solutions
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting
10. Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908
11. Environmental Tectonics Corporation Announces a Multiple Sale for Monoplace Hyperbaric Chambers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2014)... St. Francis, WI (PRWEB) November 23, 2014 ... based manufacturer and supplier of fine chemical ingredients ... industries announced the launch of its new website, ... a description of Apiscent Labs, clean design, easy ... qualities that make Apiscent Labs stand out. ...
(Date:11/22/2014)... Two new educational webinars hosted by ... ALS research and how the pharmaceutical industry can make life ... Challenge: Where Does the ALS Money Go? , Featuring guest ... Time: 1:30pm ET, Register to attend , This ... Cudkowicz, Julianne Dorn Professor of Neurology at Massachusetts General Hospital ...
(Date:11/22/2014)... During his lifetime Richard L. Sharp ... surround himself with great people and take risks to ... often marveled at his extraordinarily courageous attitude when taking ... -- even with his death impending—that’s how he continued ... would ultimately take his life. , Carrying on Sharp’s ...
(Date:11/22/2014)... Boston, MA (PRWEB) November 21, 2014 ... and key investors will gather on December 3rd ... Boston Biotech Conferences series. GeneticRx will take place ... Harvard Medical School and will discuss the present ... gene therapy, exon skipping, and gene editing—as well ...
Breaking Biology Technology:DrugDev Webinars in December to Explore What Comes Next for ALS Research and How We Can Make Life Easier for Clinical Sites 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 3Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd 2
... ... an extension of a company,s clinical team to deliver greater visibility and control over ... ... ), the leading provider of Clinical Trial Operations (CTO) software, today unveiled the ClearTrial ...
... ... ... ... ...
... NY Scientists at the U.S. Department of Energy,s Brookhaven ... bubbles that keep water from wetting a super non-stick surface. ... and the non-stick material the scientists created by "pock-marking" ... meter is being published online today in the journal ...
Cached Biology Technology:ClearTrial Launches New Service to Bring Speed and Accuracy in Clinical Trial Planning Within Reach of Smaller Biopharma Companies 2ClearTrial Launches New Service to Bring Speed and Accuracy in Clinical Trial Planning Within Reach of Smaller Biopharma Companies 3Peer-reviewed Articles Further Define Clusterin and the Role of a Clusterin Inhibitor, OGX-011, for the Treatment of Cancer 2Peer-reviewed Articles Further Define Clusterin and the Role of a Clusterin Inhibitor, OGX-011, for the Treatment of Cancer 3Peer-reviewed Articles Further Define Clusterin and the Role of a Clusterin Inhibitor, OGX-011, for the Treatment of Cancer 4Peer-reviewed Articles Further Define Clusterin and the Role of a Clusterin Inhibitor, OGX-011, for the Treatment of Cancer 5Peer-reviewed Articles Further Define Clusterin and the Role of a Clusterin Inhibitor, OGX-011, for the Treatment of Cancer 6Peer-reviewed Articles Further Define Clusterin and the Role of a Clusterin Inhibitor, OGX-011, for the Treatment of Cancer 7Scientists glimpse nanobubbles on super nonstick surfaces 2Scientists glimpse nanobubbles on super nonstick surfaces 3
(Date:11/21/2014)... , November 18, 2014 According ... Market by Systems (Video, RFID, Access Control, Intrusion Detection, ... Hotels, Banks, Government), Component Service Geography - Global Forecasts ... Market is projected to be around $25 Billion in ... 2020, growing at a CAGR of 8.69%. ...
(Date:11/21/2014)... YORK , Nov. 19, 2014  Earlier this ... at New York College, and one of the most ... biosensor signals that are transmitted from Smartphones to third ... were Smartphones and has one of the earliest known ... discussing its usage in the military, child care, elder ...
(Date:11/21/2014)... 20, 2014 Strict laws against distracted driving ... the North American and European automotive sector towards gesture ... recognition systems that are intuitive and able to retrieve ... industry. New analysis from Frost & ... in Europe and ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
... in Texas has been identified as a new genus and ... Aetodactylus halli is a pterosaur, a group of flying ... pterosaur literally a winged lizard is also one ... family Ornithocheiridae , according to paleontologist Timothy S. Myers, ...
... April 27 /PRNewswire-Asia-FirstCall/ -- Telestone Technologies,Corporation ("Telestone" ... developer,of local access networks, products, and provider of engineering ... it recently opened four,new branch offices in Zhejiang ... provinces. As a,result of forecasted sales of $10.0 ...
... ,, SAN FRANCISCO , April 27, ... announced that several of its,most popular games will be playable on Kongregate, ... through the,Kongregate platform, expanding its consumer audience, and share in revenue,generated from ... , , ...
Cached Biology News:Rare 95 million-year-old flying reptile Aetodactylus halli is new pterosaur genus, species 2Rare 95 million-year-old flying reptile Aetodactylus halli is new pterosaur genus, species 3Rare 95 million-year-old flying reptile Aetodactylus halli is new pterosaur genus, species 4Telestone Technologies Corporation Opens Four New Branch Offices 2Telestone Technologies Corporation Opens Four New Branch Offices 3Telestone Technologies Corporation Opens Four New Branch Offices 4Bigpoint Adds Kongregate to Growing List of Content Distribution Partners 2
... polyclonal antibody to human XAB2 (amino terminus) ... identified through its interaction with XPA. Immunoprecipitation ... of XAB2 interacts with the transcription-coupled repair-specific ... with RNA polymerase II. Microinjection experiments with ...
... coating using advanced automated high throughput microplate processing equipment that ... also accommodate virtually any lot size of the following formats ... 8 and 12 well strips, ... 384 well microplate, ...
...
Mynox is intended for research use only. Mynox is used for the elimination of Mycoplasma and Acholeplasma in cell and virus cultures, and other biologicals....
Biology Products: